Entry18.44→Now17.9
Undervalued preferred stock with potential for dividend resumption or par redemption. Open original source
FBIOP Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
01:06
Sep 15
Sep 15
FBIOP safe but resolution may take years
The author argues FBIOP is a fairly safe investment because the CEO owns a large stake, making it likely the situation will eventually be settled. The causal mechanism is aligned insider ownership incentivizing resolution, though the author warns it could take years. The main stated risk is the potentially very long timeline, having personally held from 13 to around 19 before losing patience.
HIGH
23:10
Sep 14
Sep 14
Undervalued preferred stock with potential for dividend resumption or par redemption.
The author argues that FBIOP is undervalued due to significant accumulated dividend arrears and the potential for dividend reinstatement or redemption at par value. The company's improved financial position, bolstered by a $200 million priority review voucher sale, increases the likelihood of resolving these arrears. The primary risk is the company's continued inability or refusal to resume payments.
HIGH
00:56
Feb 04
Feb 04
FBIOP discounted cumulative preferred with arrears priority
Author argues FBIOP preferred shares are deeply mispriced at around $12.25 versus $25 par and a 9.375% yield, with roughly $3.70 per share in cumulative dividend arrears. They claim Fortress cannot pay common dividends or buy back common stock until all preferred arrears are cleared, giving FBIOP priority on future cash flows. The catalyst is a stabilization/rebound event, potentially helped by recent FDA wins and PRV monetization; the stated risk is biotech uncertainty and no guarantee Fortress resumes its obligations.
HIGH
18:12
Jan 02
Jan 02
FBIOP preferred offers better risk/reward for CUTX-101 approval than FBIO.
The author argues FBIOP preferred stock is structurally superior to FBIO common for the CUTX-101 approval decision expected in January 2026. If approved, Fortress/Cyprium is expected to receive a Priority Review Voucher worth approximately $100M, providing cash to cover cumulative dividends and secure the balance sheet, increasing the likelihood FBIOP returns to its $25.00 par value from around $9.20-$9.35. The author estimates ~170% upside solely from returning to par, independent of market sentiment or valuation multiples.
HIGH
About FBIOP Investor Commentary
Across the available history and selected sources, Buzzberg tracks FBIOP (Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock) across 3 sources: 4 bullish vs 0 bearish calls from 3 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 4 total trade ideas tracked. Past 7 days, before deduplication: 2 bullish. Latest voices: u/DieOnYourFeat, u/Weekly-Barracuda-494, u/DebtFit2132.